211 filings
Page 8 of 11
8-K
ojx3w7 t8
7 Mar 19
Ovid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
4:13pm
8-K
4hyk2ur78i
1 Mar 19
Departure of Directors or Certain Officers
12:00am
424B5
3hgu mu1t7ylno
21 Feb 19
Prospectus supplement for primary offering
9:24pm
424B5
dfcinn
21 Feb 19
Prospectus supplement for primary offering
9:22pm
8-K
dlq670tvjrefn4w6
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
424B5
gm8xur2mzphuh4ru
19 Feb 19
Prospectus supplement for primary offering
4:06pm
424B5
oqep eyvqq
19 Feb 19
Prospectus supplement for primary offering
4:04pm
8-K
2efrhzhirfnoe0
19 Feb 19
Results of Operations and Financial Condition
4:01pm
8-K
ssz5rnn
7 Jan 19
Regulation FD Disclosure
6:31am
8-K
jgeol7jkyhba 3psj0
4 Jan 19
Other Events
8:03am
8-K
nbw 6kbvquu4fj2qwkk
17 Dec 18
Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
8:05am
8-K
rawd3 kplbgfuaml
6 Dec 18
Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
8:05am
8-K
x1vd ywr4pk5j41liy
8 Nov 18
Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress
7:40am
8-K
c8six
25 Oct 18
Regulation FD Disclosure
10:25am
8-K
xrovxhu1xpi2
1 Oct 18
Regulation FD Disclosure
12:00am
8-K
9jwtl3vhp7qso7
4 Sep 18
Departure of Directors or Certain Officers
12:00am
8-K
q152n6a
9 Aug 18
Ovid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress
12:00am